1. |
Chen G, He C, Li L, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix. BMC Cancer, 2013, 13: 249.
|
2. |
Xu Y, Liu B, Shi QL, et al. Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung. Int J Clin Exp Med, 2014, 7(8): 2120-2128.
|
3. |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386.
|
4. |
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
|
5. |
Meijer M, Rijkers GT, van Overveld FJ. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert Rev Clin Immunol, 2014, 9(11): 1055-1068.
|
6. |
李磊, 王旭辉, 李明江, 等. 胸苷激酶 1 在非小细胞肺癌 125I 粒子植入治疗疗效评估中的价值. 实用临床医学, 2017, 18(1): 37-41.
|
7. |
宁莉莉, 王宇鹏, 余飞, 等. TK1 在肺癌诊断和预后判断中的研究进展. 现代肿瘤医学, 2017, 25(7): 163-167.
|
8. |
Aufderklamm S, Todenhofer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett, 2012, 316(1): 6-10.
|
9. |
Jagarlamudi KK, Hansson LO, Eriksson S. Breast and prostate cancer patients differ significantly in their serum thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker. BMC cancer, 2015, 15: 66.
|
10. |
Ning S, Wei W, Li J, et al. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. J Cancer, 2018, 9(3): 494-501.
|
11. |
Bjöhle J, Bergqvist J, Gronowitz JS, et al. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat, 2013, 139(3): 751-758.
|
12. |
Thamm DH, Kamstock DA, Sharp CR, et al. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma. Vet Comp Oncol, 2012, 10(4): 292-302.
|
13. |
Xu XH, Zhang YM, Shu XH, et al. Serum thymidine kinase 1 reflects the progression of premalignant and malignant tumors during therapy. Mol Med Rep, 2008, 1(5): 705-711.
|
14. |
Lagunoff M. KSHV-TK: thymidine kinase or tyrosine kinase?. EMBO J, 2015, 34(4): 427-429.
|
15. |
Jeong MH, Jin YH, Kang EY, et al. The modulation of radiation-induced cell death by genistein in K562 cells: activation of thymidine kinase 1. Cell Res, 2004, 14(4): 295-302.
|
16. |
Sakamoto K, Yokogawa T, Ueno H, et al. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA. Int J Oncol, 2015, 46(6): 2327-2334.
|
17. |
Chen Z, Guan H, Yuan H, et al. Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: a case report. Oncol Lett, 2015, 10(3): 1669-1673.
|
18. |
Shintani M, Urano M, Takakuwa Y, et al. Immuno histochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. Oncol Rep, 2010, 23(5): 1345-1350.
|
19. |
Nisman B, Nechushtan H, Biran H, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol, 2014, 9(10): 1568-1572.
|
20. |
Guilleminault L, Rolland Y. Characteristics of non-pharmacological interventions in the elderly with COPD. Smoking cessation, pulmonary rehabilitation, nutritional management and patient education. Rev Mal Respir, 2018, 35(6): 626-641.
|
21. |
Strzelak A, Ratajczak A, Adamiec A, et al. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health, 2018, 15(5): pii: E1033.
|
22. |
Minnix JA, Karam Hage M, Blalock JA, et al. The importance of incorporating smoking cessation into lung cancer screening. Transl Lung Cancer Res, 2018, 7(3): 272-280.
|
23. |
Tammemägi MC. Selecting lung cancer screenees using risk prediction models-where do we go from here. Transl Lung Cancer Res, 2018, 7(3): 243-253.
|